---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-013387"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2024-10-18T23:59:59+00:00"
generated_at: "2026-05-30T12:42:23.147243+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CHMP maintains negative opinion on PTC's Translarna renewal; EC decision awaited in ~67 days

## Summary
- CHMP upheld negative opinion on renewal of conditional marketing authorization for Translarna (ataluren) in nmDMD after re-examination.
- European Commission expected to decide on opinion adoption in approximately 67 days; Translarna remains authorized pending EC review.
- CEO cites totality of evidence from three placebo-controlled trials and STRIDE registry as supportive of continued authorization.
- CHMP based decision on primary analysis subpopulation of Study 041; PTC will provide all possible evidence to EC for continued authorization.
- Translarna currently authorized in Europe; PTC continues to ensure availability for nmDMD patients during review.

## SEC filing metadata
- accession: 0001558370-24-013387
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2024-10-18T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000155837024013387/0001558370-24-013387-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000155837024013387/tmb-20241018x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-013387
- JSON: https://secwatch.observer/filing/0001558370-24-013387.json
- Plain text: https://secwatch.observer/filing/0001558370-24-013387.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.